Global Diabetic Retinopathy Market 2015-2019

糖尿病網膜症治療薬の世界市場2015-2019

◆タイトル:Global Diabetic Retinopathy Market 2015-2019
◆商品コード:IRTNTR5881
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年5月13日
◆ページ数:84
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、糖尿病網膜症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、糖尿病網膜症治療薬の世界市場規模及び予測、種類別分析、投与経路(ROA)別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

・エグゼクティブサマリー
・市場概観
・業界の構造分析
・糖尿病網膜症治療薬の世界市場:市場規模及び予測
・糖尿病網膜症治療薬の世界市場:種類別分析
・糖尿病網膜症治療薬の世界市場:投与経路(ROA)別分析
・糖尿病網膜症治療薬の世界市場:地域別分析
・市場シェア
・購買基準
・市場成長要因
・市場の課題
・市場動向
・競争状況
・主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About Diabetic Retinopathy
Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease. Laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy are some of the available treatments. One feature of diabetic retinopathy is diabetic macular edema. This is a serious medical condition involving leakage of fluid from the minute, delicate, and previously injured blood vessels located at the back of the eye, which then collects in the macula. This results in inflammation of tissue and blurry vision.

Technavio’s analysts forecast the global diabetic retinopathy market to grow at a CAGR of 6.89% over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the global diabetic retinopathy market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of prescribed as well as off-label drugs available in the market.
The report also presents the vendor landscape and a corresponding detailed analysis of the four major vendors in the market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.
Technavio’s report, Global Diabetic Retinopathy Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global diabetic retinopathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Bayer
• F. Hoffmann-La Roche
• Novartis
• Regeneron Pharmaceuticals

[Other Prominent Vendors]
• Actavis
• Alimera Sciences
• Ampio Pharmaceuticals
• Antisense Therapeutics
• BCN Peptides
• Boehringer Ingelheim
• Glycadia
• iCo Therapeutics
• Isis Pharmaceuticals
• Kowa Group
• Lpath
• Numoda Capital
• Ohr Pharmaceutical
• OPKO Health
• Parexel International
• Promedior
• pSivida
• Quark Pharmaceuticals
• R-Tech Ueno
• Sirnaomics
• ThromboGenics

[Market Driver]
• Growth in patient population
• For a full, detailed list, view our report

[Market Challenge]
• Availability of effective surgical treatments
• For a full, detailed list, view our report

[Market Trend]
• Launch of novel agents
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.3 Product Profiles
03.3.1 Lucentis
03.3.2 Eylea

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Disease Overview
06.1 Understanding the Disease
06.2 Etiology
06.2.1 Elevated Blood Glucose
06.2.2 Ischemia
06.2.3 Hypoxia
06.2.4 Neovascularization
06.2.5 Increased Permeability of Retinal Vessels
06.3 Diagnosis
06.3.1 Retinal Photography
06.3.2 Fluorescein Angiography
06.3.3 Optical Coherence Tomography
06.4 Classification
06.4.1 Proliferative Diabetic Retinopathy
06.4.2 Non-proliferative Diabetic Retinopathy
06.5 Epidemiology
06.6 Management
06.6.1 Anti-VEGF Therapy
06.6.2 Intraocular Steroid Injection
06.6.3 Laser Surgery
06.6.4 Vitrectomy

07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Key Takeaways
07.4 Five Forces Analysis

08.Pipeline Portfolio

09.Market Segmentation by Type of Molecule
09.1 Biologics
09.2 Corticosteroids

10.Market Segmentation by Route of Administration
10.1 Intravitreal
10.2 Intravenous

11.Geographical Segmentation
11.1 Diabetic Retinopathy Market in Americas
11.1.1 Market Size and Forecast
11.2 Diabetic Retinopathy Market in EMEA
11.2.1 Market Size and Forecast
11.3 Diabetic Retinopathy Market in APAC
11.3.1 Market Size and Forecast

12.Buying Criteria

13.Market Growth Drivers

14.Drivers and their Impact

15.Market Challenges

16.Impact of Drivers and Challenges

17.Market Trends

18.Trends and their Impact

19.Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Novartis
19.2.2 F. Hoffmann-La Roche
19.2.3 Regeneron Pharmaceuticals
19.2.4 Bayer
19.3 Other and Future Prominent Vendors

20.Key Vendor Analysis
20.1 Bayer
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation by Revenue 2014
20.1.4 Business Segmentation by Revenue 2013 and 2014
20.1.5 Geographical Segmentation by Revenue 2014
20.1.6 Business Strategy
20.1.7 Recent Developments
20.1.8 SWOT Analysis
20.2 F. Hoffmann-La Roche
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation
20.2.4 Business Segmentation by Revenue 2012 and 2013
20.2.5 Sales by Geography
20.2.6 Business Strategy
20.2.7 Key Information
20.2.8 SWOT Analysis
20.3 Novartis
20.3.1 Key Facts
20.3.2 Business Description
20.3.3 Business Segmentation
20.3.4 Revenue by Business Segmentation
20.3.5 Revenue Comparison 2012 and 2013
20.3.6 Sales by Geography
20.3.7 Business Strategy
20.3.8 Key Developments
20.3.9 SWOT Analysis
20.4 Regeneron Pharmaceuticals
20.4.1 Key Facts
20.4.2 Business Overview
20.4.3 Product Segmentation
20.4.4 Revenue Product Segmentation
20.4.5 Business Strategy
20.4.6 Key Information
20.4.7 SWOT Analysis

21.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Development of Diabetic Retinopathy
Exhibit 3: Classification of Diabetic Retinopathy
Exhibit 4: Snapshot of Global Diabetic Retinopathy Market
Exhibit 5: Global Diabetic Retinopathy Market 2014-2019 ($ millions)
Exhibit 6: Key Takeaways: Global Diabetic Retinopathy Market
Exhibit 7: Global Diabetic Retinopathy Market by Type of Molecule
Exhibit 8: Segmentation of Global Diabetic Retinopathy Market by Type of Molecule 2014
Exhibit 9: Global Diabetic Retinopathy Market by Route of Administration
Exhibit 10: Segmentation of Global Diabetic Retinopathy Market by Route of Administration 2014
Exhibit 11: Segmentation of Global Diabetic Retinopathy Market by Geography 2014
Exhibit 12: Segmentation of Global Diabetic Retinopathy Market by Geography 2019
Exhibit 13: Diabetic Retinopathy Market in Americas 2014-2019 ($ millions)
Exhibit 14: Diabetic Retinopathy Market in EMEA 2014-2019 ($ millions)
Exhibit 15: Diabetic Retinopathy Market in APAC 2014-2019 ($ millions)
Exhibit 16: Major Drivers of Global Diabetic Retinopathy Market
Exhibit 17: Major Challenges in Global Diabetic Retinopathy Market
Exhibit 18: Major Trends in Global Diabetic Retinopathy Market
Exhibit 19: Market Share Analysis of Vendors 2014
Exhibit 20: Global Diabetic Retinopathy Market: Revenue by Product 2014
Exhibit 21: Novartis: YoY Revenue and Growth Rate for Lucentis 2011-2014 ($ millions)
Exhibit 22: Key Takeaways: Novartis
Exhibit 23: F. Hoffmann-La Roche: YoY Revenue and Growth Rate for Lucentis 2011-2014 ($ millions)
Exhibit 24: Key Takeaways: F. Hoffmann-La Roche
Exhibit 25: Regeneron Pharmaceuticals: YoY Revenue and Growth Rate for Eylea 2011-2014 ($ millions)
Exhibit 26: Key Takeaways: Regeneron Pharmaceuticals
Exhibit 27: Bayer: YoY Revenue and Growth Rate for Eylea 2012-2014 ($ millions)
Exhibit 28: Key Takeaways: Bayer
Exhibit 29: Bayer: Business Segmentation by Revenue 2014
Exhibit 30: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 31: Bayer: Geographical Segmentation by Revenue 2014
Exhibit 32: Business Segmentation of F. Hoffmann-La Roche 2013
Exhibit 33: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 34: F. Hoffmann-La Roche: Pharmaceutical Sales by Geography 2013
Exhibit 35: F. Hoffmann-La Roche: Diagnostics Sales by Geography 2013
Exhibit 36: Novartis: Business Segmentation
Exhibit 37: Novartis: Revenue by Business Segmentation 2013
Exhibit 38: Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 39: Novartis: Revenue by Geographical Segmentation 2013
Exhibit 40: Regeneron Pharmaceuticals: Product Segmentation
Exhibit 41: Regeneron Pharmaceuticals: Revenue Product Segmentation 2013



【掲載企業】

Bayer AG, F Hoffmann-La Roche Ltd. Novartis International AG and Regeneron Pharmaceuticals Inc, Actavis, Alimera Sciences, Ampio Pharmaceuticals, Antisense Therapeutics, BCN Peptides, Boehringer Ingelheim, Glycadia, iCo Therapeutics, Isis Pharmaceuticals, Kowa Group, Lpath, Numoda Capital, OPKO Health, Ohr Pharmaceutical, Parexel International, Promedior, pSivida, Quark Pharmaceuticals, R-Tech Ueno, Sirnaomics, ThromboGenics

【資料のキーワード】

糖尿病網膜症治療薬、増殖性糖尿病性網膜症、糖尿病性黄斑浮腫、糖尿病、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[糖尿病網膜症治療薬の世界市場2015-2019]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆